|drug3728||Standard of Care Wiki||0.16|
|D030341||Nidovirales Infections NIH||0.71|
|D003333||Coronaviridae Infections NIH||0.45|
|D007154||Immune System Diseases NIH||0.41|
|D012327||RNA Virus Infections NIH||0.41|
|D008171||Lung Diseases, NIH||0.20|
|D012140||Respiratory Tract Diseases NIH||0.19|
|D012141||Respiratory Tract Infections NIH||0.16|
|D011024||Pneumonia, Viral NIH||0.11|
|D014777||Virus Diseases NIH||0.11|
|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.
Description: To determine the effect of favipiravir + SOC v. SOC on viral clearance of COVID-19 as measured by nasopharyngeal and oropharyngeal samplingMeasure: Time to viral clearance Time: Day 29
Description: To determine the clinical benefit of administering favipiravir plus SOC compared to SOC alone, clinical benefit will be measured using a study-specified ordinal scale on Day 15 in adult patients hospitalized with COVID-19.Measure: Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15 Time: through Day 15
Description: The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, temperature.Measure: Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2) Time: through Day 29
Description: Measurement of maximum plasma concentrationMeasure: Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax) Time: through Day 14
Description: Measurement of minimum plasma concentrationMeasure: Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin Time: through Day 14
Description: Measurement of the area under the curve of plasma concentration versus time profileMeasure: Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC Time: through Day 14
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports